The Molecular Biology Laboratory in the local health authority’s (ASUGI) Anatomical Pathology Department has obtained EMQN 2023 Certification. The European Molecular Genetics Quality Network (EMQN) awarded this important European certification in recognition of the laboratory’s activities in the analysis of prognostic-predictive markers in the field of oncology.

The accreditation is crucial for authorising the purchase of very expensive drugs for patients.

In the past, ASUGI could only evaluate a small number of markers for a few types of tumours. The accreditation increases the number of markers and tumours the lab can analyse, guaranteeing more treatment possibilities.

This year, the Anatomical Pathology Laboratory has seen a significant increase in activity, and by the beginning of February 2024, the new state-of-the-art instrumentation that also allows for second-line oncological examinations should be up and running.

‘What has been achieved in terms of clinical oncology diagnostic services, provided for patients, has been made possible thanks to collaboration between hospital and university staff from the various laboratories within the Anatomical Pathology Department, allowing for an optimisation of the material used in analyses. The molecular laboratory staff have also played an essential role, contributing to the execution and interpretation of tests and working harmoniously with the support of clinical professionals across the various sectors involved. In addition, in this field, the Anatomical Pathology Department has been able to count on a sizeable contribution from LILT (an Italian foundation funding research into tumours) to equip itself with state-of-the-art equipment and research funding in order to develop the field of tumour biomarkers in liquid biopsy,' says Prof. Fabrizio Zanconati, professor of Anatomical Pathology at UniTS and Director of the Pathological Anatomy and Histology Unit.